Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Vaginal pH measured in vivo: lactobacilli determine pH and lactic acid concentration.

O'Hanlon DE, Come RA, Moench TR.

BMC Microbiol. 2019 Jan 14;19(1):13. doi: 10.1186/s12866-019-1388-8.

2.

Anti-HIV-1 Activity of Lactic Acid in Human Cervicovaginal Fluid.

Tyssen D, Wang YY, Hayward JA, Agius PA, DeLong K, Aldunate M, Ravel J, Moench TR, Cone RA, Tachedjian G.

mSphere. 2018 Jul 5;3(4). pii: e00055-18. doi: 10.1128/mSphere.00055-18.

3.

Pharmacokinetics and Preliminary Safety of Pod-Intravaginal Rings Delivering the Monoclonal Antibody VRC01-N for HIV Prophylaxis in a Macaque Model.

Zhao C, Gunawardana M, Villinger F, Baum MM, Remedios-Chan M, Moench TR, Zeitlin L, Whaley KJ, Bohorov O, Smith TJ, Anderson DJ, Moss JA.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e02465-16. doi: 10.1128/AAC.02465-16. Print 2017 Jul.

4.

Biomarkers and biometric measures of adherence to use of ARV-based vaginal rings.

Stalter RM, Moench TR, MacQueen KM, Tolley EE, Owen DH; Consortium for Ring Adherence.

J Int AIDS Soc. 2016 May 2;19(1):20746. doi: 10.7448/IAS.19.1.20746. eCollection 2016. Review.

5.

Cell-associated transmission of HIV type 1 and other lentiviruses in small-animal models.

Moench TR.

J Infect Dis. 2014 Dec 15;210 Suppl 3:S654-9. doi: 10.1093/infdis/jiu368. Review.

6.

Vaginal pH and microbicidal lactic acid when lactobacilli dominate the microbiota.

O'Hanlon DE, Moench TR, Cone RA.

PLoS One. 2013 Nov 6;8(11):e80074. doi: 10.1371/journal.pone.0080074. eCollection 2013.

7.

Evaluation of microbicide gel adherence monitoring methods.

Moench TR, O'Hanlon DE, Cone RA.

Sex Transm Dis. 2012 May;39(5):335-40. doi: 10.1097/OLQ.0b013e31824790bb.

PMID:
22504592
8.

Optical coherence tomography compared with colposcopy for assessment of vaginal epithelial damage: a randomized controlled trial.

Vincent KL, Stanberry LR, Moench TR, Breitkopf CR, Loza ML, Wei J, Grady J, Paull J, Motamedi M, Rosenthal SL.

Obstet Gynecol. 2011 Dec;118(6):1354-61. doi: 10.1097/AOG.0b013e318238f563.

9.

SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans.

Price CF, Tyssen D, Sonza S, Davie A, Evans S, Lewis GR, Xia S, Spelman T, Hodsman P, Moench TR, Humberstone A, Paull JR, Tachedjian G.

PLoS One. 2011;6(9):e24095. doi: 10.1371/journal.pone.0024095. Epub 2011 Sep 15.

10.

In vaginal fluid, bacteria associated with bacterial vaginosis can be suppressed with lactic acid but not hydrogen peroxide.

O'Hanlon DE, Moench TR, Cone RA.

BMC Infect Dis. 2011 Jul 19;11:200. doi: 10.1186/1471-2334-11-200.

11.

Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women.

Abdool Karim SS, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, Taha T, Kapina M, Maslankowski L, Coletti A, Profy A, Moench TR, Piwowar-Manning E, Mâsse B, Hillier SL, Soto-Torres L; HIV Prevention Trials Network (HPTN) 035 Study Team.

AIDS. 2011 Apr 24;25(7):957-66. doi: 10.1097/QAD.0b013e32834541d9.

12.

Microbicide excipients can greatly increase susceptibility to genital herpes transmission in the mouse.

Moench TR, Mumper RJ, Hoen TE, Sun M, Cone RA.

BMC Infect Dis. 2010 Nov 18;10:331. doi: 10.1186/1471-2334-10-331.

13.

An acceptability and safety study of the Duet cervical barrier and gel delivery system in Zimbabwe.

Montgomery ET, Woodsong C, Musara P, Cheng H, Chipato T, Moench TR, Spielberg F, van der Straten A.

J Int AIDS Soc. 2010 Aug 5;13:30. doi: 10.1186/1758-2652-13-30.

14.

Cervicovaginal fluid and semen block the microbicidal activity of hydrogen peroxide produced by vaginal lactobacilli.

O'Hanlon DE, Lanier BR, Moench TR, Cone RA.

BMC Infect Dis. 2010 May 19;10:120. doi: 10.1186/1471-2334-10-120.

15.

Formulating a sulfonated antiviral dendrimer in a vaginal microbicidal gel having dual mechanisms of action.

Mumper RJ, Bell MA, Worthen DR, Cone RA, Lewis GR, Paull JR, Moench TR.

Drug Dev Ind Pharm. 2009 May;35(5):515-24. doi: 10.1080/03639040802488097.

16.

Hormonal contraception and the risks of STI acquisition: results of a feasibility study to plan a future randomized trial.

Hubacher D, Raymond ER, Beksinska M, Delany-Moretlwe S, Smit J, Hylton-Kong T, Moench TR.

Contraception. 2008 May;77(5):366-70. doi: 10.1016/j.contraception.2008.01.006. Epub 2008 Mar 18.

PMID:
18402854
17.

A Phase I study of the functional performance, safety and acceptability of the BufferGel Duet.

Ballagh SA, Brache V, Mauck C, Callahan MM, Cochon L, Wheeless A, Moench TR.

Contraception. 2008 Feb;77(2):130-7. doi: 10.1016/j.contraception.2007.10.003. Epub 2007 Dec 27.

PMID:
18226678
18.

Contraceptive efficacy of a novel spermicidal microbicide used with a diaphragm: a randomized controlled trial.

Barnhart KT, Rosenberg MJ, MacKay HT, Blithe DL, Higgins J, Walsh T, Wan L, Thomas M, Creinin MD, Westhoff C, Schlaff W, Archer DF, Ayers C, Kaunitz A, Das S, Moench TR.

Obstet Gynecol. 2007 Sep;110(3):577-86.

PMID:
17766603
19.

Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission.

Cone RA, Hoen T, Wong X, Abusuwwa R, Anderson DJ, Moench TR.

BMC Infect Dis. 2006 Jun 1;6:90.

20.

In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials.

Tien D, Schnaare RL, Kang F, Cohl G, McCormick TJ, Moench TR, Doncel G, Watson K, Buckheit RW, Lewis MG, Schwartz J, Douville K, Romano JW.

AIDS Res Hum Retroviruses. 2005 Oct;21(10):845-53.

PMID:
16225411
21.

Low pH immobilizes and kills human leukocytes and prevents transmission of cell-associated HIV in a mouse model.

Olmsted SS, Khanna KV, Ng EM, Whitten ST, Johnson ON 3rd, Markham RB, Cone RA, Moench TR.

BMC Infect Dis. 2005 Sep 30;5:79.

22.

Safety and acceptability of penile application of 2 candidate topical microbicides: BufferGel and PRO 2000 Gel: 3 randomized trials in healthy low-risk men and HIV-positive men.

Tabet SR, Callahan MM, Mauck CK, Gai F, Coletti AS, Profy AT, Moench TR, Soto-Torres LE, Poindexter III AN, Frezieres RG, Walsh TL, Kelly CW, Richardson BA, Van Damme L, Celum CL.

J Acquir Immune Defic Syndr. 2003 Aug 1;33(4):476-83. Erratum in: J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):118.

PMID:
12869836
23.

A self-sampling method to obtain large volumes of undiluted cervicovaginal secretions.

Boskey ER, Moench TR, Hees PS, Cone RA.

Sex Transm Dis. 2003 Feb;30(2):107-9.

PMID:
12567165
24.

Microbicide efficacy and toxicity tests in a mouse model for vaginal transmission of Chlamydia trachomatis.

Achilles SL, Shete PB, Whaley KJ, Moench TR, Cone RA.

Sex Transm Dis. 2002 Nov;29(11):655-64.

PMID:
12438901
25.

Human monoclonal antibody stability and activity at vaginal pH.

Castle PE, Karp DA, Zeitlin L, García-Moreno E B, Moench TR, Whaley KJ, Cone RA.

J Reprod Immunol. 2002 Jul-Aug;56(1-2):61-76.

PMID:
12106884
26.

Microflora changes with the use of a vaginal microbicide.

Clarke JG, Peipert JF, Hillier SL, Heber W, Boardman L, Moench TR, Mayer K.

Sex Transm Dis. 2002 May;29(5):288-93.

PMID:
11984446
27.
28.

Vaginal transmission of cell-associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent.

Khanna KV, Whaley KJ, Zeitlin L, Moench TR, Mehrazar K, Cone RA, Liao Z, Hildreth JE, Hoen TE, Shultz L, Markham RB.

J Clin Invest. 2002 Jan;109(2):205-11.

29.

Diffusion of macromolecules and virus-like particles in human cervical mucus.

Olmsted SS, Padgett JL, Yudin AI, Whaley KJ, Moench TR, Cone RA.

Biophys J. 2001 Oct;81(4):1930-7.

30.

Preventing disease by protecting the cervix: the unexplored promise of internal vaginal barrier devices.

Moench TR, Chipato T, Padian NS.

AIDS. 2001 Sep 7;15(13):1595-602. Review. No abstract available.

PMID:
11546933
31.

Origins of vaginal acidity: high D/L lactate ratio is consistent with bacteria being the primary source.

Boskey ER, Cone RA, Whaley KJ, Moench TR.

Hum Reprod. 2001 Sep;16(9):1809-13.

PMID:
11527880
32.

Tests of Buffergel for contraception and prevention of sexually transmitted diseases in animal models.

Zeitlin L, Hoen TE, Achilles SL, Hegarty TA, Jerse AE, Kreider JW, Olmsted SS, Whaley KJ, Cone RA, Moench TR.

Sex Transm Dis. 2001 Jul;28(7):417-23.

PMID:
11460027
33.

Preventing infectious disease with passive immunization.

Zeitlin L, Cone RA, Moench TR, Whaley KJ.

Microbes Infect. 2000 May;2(6):701-8. Review.

PMID:
10884621
34.

The rate at which human sperm are immobilized and killed by mild acidity.

Olmsted SS, Dubin NH, Cone RA, Moench TR.

Fertil Steril. 2000 Apr;73(4):687-93.

PMID:
10731526
35.

Neglected opportunities.

Moench TR.

J Infect Dis. 2000 Feb;181(2):804-5. No abstract available.

PMID:
10669386
36.

Acid production by vaginal flora in vitro is consistent with the rate and extent of vaginal acidification.

Boskey ER, Telsch KM, Whaley KJ, Moench TR, Cone RA.

Infect Immun. 1999 Oct;67(10):5170-5.

37.

Comparison of an anti-HSV-2 monoclonal IgG and its IgA switch variant for topical immunoprotection of the mouse vagina.

Zeitlin L, Castle PE, Whaley KJ, Moench TR, Cone RA.

J Reprod Immunol. 1998 Oct;40(1):93-101.

PMID:
9862259
38.

A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes.

Zeitlin L, Olmsted SS, Moench TR, Co MS, Martinell BJ, Paradkar VM, Russell DR, Queen C, Cone RA, Whaley KJ.

Nat Biotechnol. 1998 Dec;16(13):1361-4.

PMID:
9853620
39.

Tests of vaginal microbicides in the mouse genital herpes model.

Zeitlin L, Whaley KJ, Hegarty TA, Moench TR, Cone RA.

Contraception. 1997 Nov;56(5):329-35.

PMID:
9437563
40.

Contraceptive effect of sperm-agglutinating monoclonal antibodies in rabbits.

Castle PE, Whaley KJ, Hoen TE, Moench TR, Cone RA.

Biol Reprod. 1997 Jan;56(1):153-9.

PMID:
9002644
41.
42.

Topically applied human recombinant monoclonal IgG1 antibody and its Fab and F(ab')2 fragments protect mice from vaginal transmission of HSV-2.

Zeitlin L, Whaley KJ, Sanna PP, Moench TR, Bastidas R, De Logu A, Williamson RA, Burton DR, Cone RA.

Virology. 1996 Nov 1;225(1):213-5.

43.

Brain endothelial cell infection in children with acute fatal measles.

Esolen LM, Takahashi K, Johnson RT, Vaisberg A, Moench TR, Wesselingh SL, Griffin DE.

J Clin Invest. 1995 Nov;96(5):2478-81.

44.

Infection of monocytes during measles.

Esolen LM, Ward BJ, Moench TR, Griffin DE.

J Infect Dis. 1993 Jul;168(1):47-52.

PMID:
8515132
45.
47.
48.

Epidemiologic observations on feline immunodeficiency virus and Toxoplasma gondii coinfection in cats in Baltimore, Md.

Witt CJ, Moench TR, Gittelsohn AM, Bishop BD, Childs JE.

J Am Vet Med Assoc. 1989 Jan 15;194(2):229-33.

PMID:
2537272
49.

Acute measles in patients with and without neurological involvement: distribution of measles virus antigen and RNA.

Moench TR, Griffin DE, Obriecht CR, Vaisberg AJ, Johnson RT.

J Infect Dis. 1988 Aug;158(2):433-42.

PMID:
3042879
50.

Basis of neurovirulence in Sindbis virus encephalomyelitis of mice.

Jackson AC, Moench TR, Trapp BD, Griffin DE.

Lab Invest. 1988 May;58(5):503-9.

PMID:
3367635

Supplemental Content

Loading ...
Support Center